Skip to Content

Posts tagged with "Press Coverage"

  • Press Coverage

    An Alzheimer’s Cure? Not So Fast.

    The British press (and to a lesser extent, the US one) was full of reports the other day about some startling breakthrough in Alzheimer’s research. We could certainly use one, but is this it? What would an Alzheimer’s breakthrough look like, anyway? Given the complexity of the disease, and the difficulty of extrapolating from its… Read More
  • Cancer

    Overselling p53 Drugs

    You may have seen some “wonder drug” news stories over the holiday break about compounds targeting p53 – many outlets picked up this New York Times story. The first paragraph probably got them: For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of… Read More
  • Chemical Biology

    More on the Parabon NSF Press Release

    Well, I’ve been away from the computer a good part of the day, but I return to find that the author of the NSF press release that I spoke unkindly of has shown up in the comments to that post. I’m going to bring those up here to make sure that his objections get a… Read More
  • Chemical Biology

    Parabon’s DNA Structures: What The Hey?

    I’m having a real problem understanding this press release from the NSF. I’ve been looking at it for a few days now (it’s been sent to me a couple of times in e-mail), and I still can’t get a handle on it. And I’m not the only one. I see just this morning that Chemobber… Read More
  • Press Coverage

    Pfizer’s Gold Dust Makes it to the WSJ

    I wanted to congratulate the commenters around here – your knowledge (and your low-pH wit) have propelled the Pfizer gold dust speculation here to Peter Loftus’ Corporate Intelligence blog at the Wall Street Journal. Don’t expect any response from Pfizer, though. . . Read More
  • Clinical Trials

    Oh Yeah, Now That You Mention It, They’re Dead

    The overhyped nature of stem cell therapies is a topic that’s come up here several times. In the latest developments, Pluristem, Inc., is threatening to sue Bloomberg New for their recent report, titled “Girl Dies As Pluristem Sells On Gains With Miracle Cells”. Gosh, it’s hard to see why the company would take exception to… Read More
  • Cancer

    CNN’s Cure for Cancer

    I’ve been meaning to write something about the M.D. Anderson announcement of “Moon Shot” programs for cancer therapies. Mostly something about how I’m very glad that they’re spending a lot of time and money on this, because there are a lot of good people there, but also about how I truly hate the “Moon Shot”… Read More
  • Press Coverage

    Drug Discovery on Radio 4

    Several readers sent along a link to this Radio 4 program (“The End of Drug Disocvery”) from the BBC on drug discovery. From what I’ve heard, it’s a very good overview of the current state of the field for people outside it, and gets across just how difficult it’s been to find good drug candidates. Read More
  • General Scientific News

    Nobel Prizes in Chemistry For People Who Aren’t Chemists

    Nobelist Roald Hoffman has directly taken on a topic that many chemists find painful: why aren’t more chemistry Nobel prizes given, to, well. . .chemists? “. . .the last decade has been especially unkind to “pure” chemists, asa only four of ten Nobel awards could be classified as rewarding work comfortably ensconced in chemi… Read More
  • Cancer

    Avastin Coverage, Amended

    In response to the press coverage on the FDA’s Avastin decision on Friday, a reader forwarded a revised and extended version of the New York TImes article that appeared soon afterwards. Here are some excerpts, which I think get across the thinking of many medicinal chemists and drug researchers. His contributions are bolded for emphasis… Read More
...345...